Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
1990-12-27
|
| pubmed:abstractText |
In order to investigate the antitumor effect of recombinant human interleukin-1 beta (IL-1 beta) alone and in combination with natural human tumor necrosis factor-alpha (nHuTNF-alpha), we used female BDF1 mice bearing Lewis lung carcinoma (3LL). IL-1 beta showed an antiproliferative effect against pulmonary metastatic tumors of 3LL in a dose-dependent manner. We observed 19.6 +/- 6.6, 18.6 +/- 5.3, 14.1 +/- 4.4 and 13.0 +/- 6.0 metastatic tumors at doses of 0.5, 1.0, 2.5 and 5.0 micrograms IL-1 beta/mouse/day by daily intravenous administration (the number of metastatic tumors of the control group was 26.3 +/- 8.2). Similar results were obtained by intraperitoneal administration, but in this case, mice showed a marked decrease of body weight. When IL-1 beta was administered in combination with nHuTNF-alpha, pulmonary metastatic tumors decreased much more than when IL-1 beta was administered alone. When the control group had 18.6 +/- 12.7 metastatic tumors, the nHuTNF-alpha group had 12.3 +/- 3.9 and the IL-1 beta group had 12.8 +/- 8.0, the group which was administered both cytokines had a significantly decreased number of 5.6 +/- 3.3 metastatic tumors. This antiproliferative effect of IL-1 beta in combination with nHuTNF-alpha was reduced by the intravenous administration of anti-asialo GM1 antibody and carrageenan. The number of metastatic tumors was increased from 8.9 +/- 8.0 to 18.8 +/- 11.4 by anti-asialo GM1 antibody and from 9.5 +/- 6.8 to 28.0 +/- 12.3 by carrageenan. It was suggested that asialo GM1-positive cells and macrophage were two of the most important effectors of the antiproliferative effect of IL-1 beta and TNF-alpha.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Carrageenan,
http://linkedlifedata.com/resource/pubmed/chemical/G(M1) Ganglioside,
http://linkedlifedata.com/resource/pubmed/chemical/Glycosphingolipids,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/asialo GM1 ganglioside
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0910-5050
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
81
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1026-31
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2121675-Animals,
pubmed-meshheading:2121675-Antibodies,
pubmed-meshheading:2121675-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2121675-Carrageenan,
pubmed-meshheading:2121675-Cell Division,
pubmed-meshheading:2121675-Drug Administration Schedule,
pubmed-meshheading:2121675-Drug Synergism,
pubmed-meshheading:2121675-Female,
pubmed-meshheading:2121675-G(M1) Ganglioside,
pubmed-meshheading:2121675-Glycosphingolipids,
pubmed-meshheading:2121675-Humans,
pubmed-meshheading:2121675-Interleukin-1,
pubmed-meshheading:2121675-Leukocyte Count,
pubmed-meshheading:2121675-Lung Neoplasms,
pubmed-meshheading:2121675-Mice,
pubmed-meshheading:2121675-Mice, Inbred Strains,
pubmed-meshheading:2121675-Recombinant Proteins,
pubmed-meshheading:2121675-Time Factors,
pubmed-meshheading:2121675-Tumor Necrosis Factor-alpha
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha.
|
| pubmed:affiliation |
First Department of Surgery, Okayama University Medical School.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|